BRAF-mutant Non-Small Cell Lung Cancer Pipeline: 10+ Companies Advancing Targeted Therapies to Transform BRAF+ NSCLC Treatment | DelveInsight

The treatment landscape for BRAF-mutant Non-Small Cell Lung Cancer (BRAF+ NSCLC), a molecular subtype of NSCLC driven by mutations in the BRAF gene, most commonly the V600E mutation, is rapidly evolving. Traditionally associated with poor prognosis, BRAF+ NSCLC has witnessed significant clinical progress with the development of targeted therapies that inhibit aberrant MAPK pathway signaling. With growing recognition of the heterogeneity and aggressiveness of BRAF-driven tumors, biopharmaceutical companies are increasingly focused on refining treatment regimens with next-generation BRAF inhibitors, combination therapies (e.g., BRAF/MEK inhibition), and immuno-oncology strategies to improve survival outcomes and minimize resistance.

DelveInsight's "BRAF-mutant Non-Small Cell Lung Cancer - Pipeline Insight, 2025" offers a detailed overview of the global R&D landscape, profiling emerging clinical and preclinical drug candidates with novel mechanisms of action. The report covers innovative strategies, including dual pathway inhibition (BRAF and MEK), pan-RAF inhibitors, ERK inhibitors, and synergistic approaches with immune checkpoint inhibitors. It also explores biomarker-guided trial designs, breakthrough therapy designations, and collaborative efforts accelerating development timelines.

As BRAF-mutant NSCLC accounts for ~2-4% of all NSCLC cases and remains a key molecular target in precision oncology, this report sheds light on the companies, including Pierre Fabre Medicament, Xynomic Pharmaceuticals, Kinnate Biopharma, and Revolution Medicines, leading the charge toward personalized treatment strategies. With a focus on overcoming resistance, enhancing durability of response, and expanding therapeutic access, the BRAF+ NSCLC pipeline promises to redefine standards of care and deliver meaningful clinical benefits to patients.

Interested in learning more about the current treatment landscape and the key drivers shaping the BRAF-mutant non-small cell lung cancer pipeline? Click here: https://www.delveinsight.com/report-store/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's BRAF-mutant non-small cell lung cancer pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for BRAF-mutant non-small cell lung cancer treatment.
• The leading BRAF-mutant non-small cell lung cancer companies include Pierre Fabre Medicament, Xynomic Pharmaceuticals, Kinnate Biopharma, Revolution Medicines, Black Diamond Therapeutics, and others are evaluating their lead assets to improve the BRAF-mutant non-small cell lung cancer treatment landscape.
• Key BRAF-mutant Non-Small Cell Lung Cancer pipeline therapies in various stages of development include Encorafenib/Binimetinib, XP-102, KIN-2787, RMC-4630, BDTX-4933, and others.
• In May 2025, Lantern Pharma Inc. (Nasdaq: LTRN) announced FDA clearance of an IND amendment to start a Phase Ib/II trial of LP-184 in genomically defined non-small cell lung cancer patients, aiming to improve outcomes.
• In May 2025, AbbVie (NYSE: ABBV) announced that the FDA granted accelerated approval to EMRELISTM (telisotuzumab vedotin-tllv) for treating adults with locally advanced or metastatic non-squamous non-small cell lung cancer exhibiting high c-Met protein overexpression (≥50% tumor cells with strong staining) after prior systemic therapy.
• In April 2025, Verastem Oncology received FDA clearance for its IND application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, and plans to begin a Phase I/IIa study by mid-year targeting advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.
• In March 2025, CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for lead compound CER-1236. This will allow the company to proceed with a Phase I clinical trial in advanced solid tumors, including non-small cell lung cancer and ovarian cancer.
• In March 2025, Johnson & Johnson announced that new data from its oncology pipeline, including overall survival results from the Phase III MARIPOSA study, will be presented at the 2025 European Lung Cancer Congress. The study evaluates RYBREVANT® (amivantamab-vmjw) plus LAZCLUZETM (lazertinib) versus osimertinib in first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.
• In December 2024, Xcovery Holdings, Inc., an oncology-focused pharmaceutical company, announced FDA approval of ensartinib (Ensacove) for treating ALK-positive locally advanced or metastatic non-small cell lung cancer.

Request a sample and discover the recent breakthroughs happening in the BRAF-mutant non-small cell lung cancer pipeline landscape at https://www.delveinsight.com/report-store/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

BRAF-mutant Non-Small Cell Lung Cancer Overview
About 80-85% of lung cancers are classified as Non-Small Cell Lung Cancer (NSCLC), which includes three primary subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes originate from different lung cells but are grouped under NSCLC due to their similar treatment approaches and prognostic outcomes.

BRAF-mutant lung cancer represents a rare subset of NSCLC, occurring in approximately 4% of cases, most commonly within adenocarcinomas. The BRAF V600E mutation, in particular, is found in around 1-2% of NSCLC patients and is more frequently observed in individuals with a history of smoking.

The BRAF gene encodes a protein that regulates cell growth. When mutated, especially in the V600E variant, it produces an abnormal protein that continuously activates cell signaling pathways, specifically the MEK pathway, leading to uncontrolled cell proliferation. Among the various BRAF mutations, V600E is the only one currently targeted by FDA-approved therapies for lung cancer.

Find out more about BRAF-mutant non-small cell lung cancer medication at https://www.delveinsight.com/report-store/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

BRAF-mutant Non-Small Cell Lung Cancer Treatment Analysis: Drug Profile
Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib), a BRAF kinase inhibitor, is approved in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma harboring a BRAFV600 mutation. This combination is currently under investigation in a Phase II clinical trial for patients with metastatic BRAFV600-mutant Non-Small Cell Lung Cancer (NSCLC), with trial completion anticipated by March 2025. Additionally, the combination is being evaluated across various other cancer indications.

XP-102: Xynomic Pharmaceuticals, Inc.
XP-102 is a second-generation, potent, and selective pan-RAF inhibitor that targets the DFG-out conformation, in contrast to existing BRAF inhibitors, which bind the DFG-in conformation. It shows promise as a novel therapeutic option for BRAF V600-mutated solid tumors, including colorectal cancer, non-small cell lung cancer (NSCLC), and hairy-cell leukemia. XP-102 is currently in Phase I/II clinical development for multiple tumors, including NSCLC, with study completion expected by December 2024.

Learn more about the novel and emerging BRAF-mutant non-small cell lung cancer pipeline therapies at https://www.delveinsight.com/report-store/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

BRAF-mutant Non-Small Cell Lung Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the BRAF-mutant Non-Small Cell Lung Cancer Pipeline Report
• Coverage: Global
• Key BRAF-mutant Non-Small Cell Lung Cancer Companies: Pierre Fabre Medicament, Xynomic Pharmaceuticals, Kinnate Biopharma, Revolution Medicines, Black Diamond Therapeutics, and others.
• Key BRAF-mutant Non-Small Cell Lung Cancer Pipeline Therapies: Encorafenib/Binimetinib, XP-102, KIN-2787, RMC-4630, BDTX-4933, and others.

Dive deep into rich insights for drugs used for BRAF-mutant non-small cell lung cancer treatment, visit: https://www.delveinsight.com/report-store/braf-mutant-non-small-cell-lung-cancer-braf-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. BRAF-mutant Non-Small Cell Lung Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. BRAF-mutant Non-Small Cell Lung Cancer Pipeline Therapeutics
6. BRAF-mutant Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
7. BRAF-mutant Non-Small Cell Lung Cancer Pipeline: Mid-Stage Products (Phase II)
8. BRAF-mutant Non-Small Cell Lung Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.